Proteome Sciences PLC Appointment of Richard Dennis as CCO (2561B)
April 03 2017 - 2:00AM
UK Regulatory
TIDMPRM
RNS Number : 2561B
Proteome Sciences PLC
03 April 2017
Proteome Sciences plc
(the "Company" or the "Group")
Appointment of Richard Dennis as Chief Commercial Officer
The Company is pleased to confirm that Richard Dennis has joined
us as Chief Commercial Officer, the first person to hold such a
role at Proteome Sciences. Richard brings over 30 years' experience
of strategic sales and marketing, combined with significant
technical knowledge, gained most recently as Director of
International Commercial Operations at Quanterix Corp. where he was
instrumental in establishing successful sales organisations in
Europe, Japan and China. Previously he had held positions of
increasing commercial responsibility at Bioscale Inc. and Meso
Scale Discovery.
Richard Dennis commented: "I have been involved with proteins
throughout my commercial career and am excited to be joining
Proteome Sciences at this time. Never has the 'power of the
protein' been better understood by, and more important to, the
scientific community. Proteome Sciences can fully exploit this
potential and I look forward to leading the commercial team to
achieve this."
Jeremy Haigh, Chief Executive Officer, commented: "Given the
critical importance of commercialising our biomarker services to
the future success of Proteome Sciences, I am delighted to welcome
Richard Dennis to the Company as our first Chief Commercial
Officer. His experience of building successful sales organisations
across the world makes him a hugely valuable addition to the
Company and I look forward to working with him as he executes a
commercial plan for the services business and provides integrated
commercial leadership for the Company."
For further information:
Proteome Sciences plc
Dr Jeremy Haigh, Chief Executive Officer Tel:
+44 (0)1932 865065
Dr Ian Pike, Chief Scientific
Officer
Geoff Ellis, Finance Director
finnCap Limited (Nominated
Adviser/Broker) Tel: +44 (0)20 7220
Geoff Nash/James Thompson 0500
Tony Quirke (broking)
IFC Advisory (Financial PR and IR)
Tim Metcalfe/Graham Tel: +44 (0)20 3053
Herring/Miles Nolan 8671
Notes for editors:
Proteome Sciences is a leader in applied proteomics offering
high sensitivity, proprietary technologies and workflows for
mapping cell signalling pathways (SysQuant(R) , TMTcalibrator(TM) )
and for the discovery, validation and assay development of protein
biomarkers. The company has its headquarters in Cobham, UK, with
laboratory facilities in London, UK and in Frankfurt, Germany from
where the PS Biomarker Services(TM) division provides outsourced
proteomics services and proprietary biomarker assays to
biopharmaceutical and diagnostics companies and to academia.
Proteome Sciences has patented a number of novel protein
biomarkers for diagnostic and treatment applications in important
areas of human therapeutics such as cancer, stroke and Alzheimer's
disease, and these are available for license.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSDIFMFFWSEED
(END) Dow Jones Newswires
April 03, 2017 02:00 ET (06:00 GMT)
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Apr 2024 to May 2024
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From May 2023 to May 2024